Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial

被引：0
|
作者：
Kelsen, D. [1 ]
Jhawer, M. [1 ]
Ilson, D. [1 ]
Tse, A. [1 ]
Randazzo, J. [1 ]
Robinson, E. [1 ]
Capanu, M. [1 ]
Shah, M. A. [1 ]
机构：
[1] MSKCC, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4512
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma
    Shah, Manish A.
    Jhawer, Minaxi
    Ilson, David H.
    Lefkowitz, Robert A.
    Robinson, Edric
    Capanu, Marinela
    Kelsen, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07) : 868 - 874
  • [2] Quality of life in patients with advanced gastroesophageal (GE) adenocarcinoma treated with modified docetaxel, cisplatin, and fluorouracil (mDCF)
    Smyth, E. C.
    Janjigian, Y. Y.
    Robinson, E.
    Sheehy, E. C.
    Karpenko, I.
    Capanu, M.
    Kelsen, D. P.
    Shah, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [3] Phase II study of mFOLFOX with bevacizumab (Bev) in metastatic gastroesophageal and gastric (GE) adenocarcinoma (AC).
    Li, Jia
    Kortmansky, Jeremy S.
    Fischbach, Neal A.
    Stein, Stacey
    Yao, Xiaopan
    Hochster, Howard S.
    Lacy, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Random assignment multicenter phase II studyof modified docetwel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE)
    Shah, M. A.
    Shibata, S.
    Stoller, R. G.
    Kemeny, M.
    Ritch, P. S.
    Krishnamurthi, S. S.
    Su, Y. B.
    Janjigian, Y. Y.
    Capanu, M.
    Kelsen, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447).
    Shah, M. A.
    Ramanathan, R. K.
    Ilson, D.
    Randazzo, J.
    Schwartz, G. K.
    Tse, A.
    D'Adamo, D.
    Levner, A.
    Capanu, M.
    Kelsen, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 183S - 183S
  • [6] Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer
    Enzinger, P. C.
    Ryan, D. P.
    Regan, E. M.
    Lehman, N.
    Abrams, T. A.
    Hezel, A. F.
    Fidias, P.
    Sequist, L. V.
    Blaszkowsky, L. S.
    Fuchs, C. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] PHASE II TRIAL OF DOCETAXEL, CISPLATIN, IRINOTECAN, AND BEVACIZUMAB IN METASTATIC ESOPHAGOGASTRIC CANCER
    Enzinger, P.
    Fidias, P.
    Regan, E.
    Lehman, N.
    Abrams, T.
    Hezel, A.
    Sequist, L.
    Fuchs, C.
    Ryan, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 171 - 172
  • [8] A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Shah, MA
    Ilson, D
    Ramanathan, RK
    Levner, A
    D'Adamo, D
    Schwartz, L
    Casper, E
    Schwartz, GK
    Kelsen, DP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 314S - 314S
  • [9] Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma
    Ajani, JA
    Fodor, MB
    Tjulandin, SA
    Moiseyenko, VM
    Chao, Y
    Filho, SC
    Cabral, S
    Majlis, A
    Assadourian, S
    Van Cutsem, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5660 - 5667
  • [10] Phase II study of mFOLFOX6 with bevacizumab (Bev) in metastatic gastric and esophageal (GE) adenocarcinoma
    Li, J.
    Kortmansky, J. S.
    Saif, M.
    Fischbach, N. A.
    Ravage-Mass, L.
    Elligers, K.
    Hahn, C.
    Cohenuram, M. K.
    Lacy, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345